U.S. Water Utilities Stock News

Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you. The stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week. Recent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...

If you are wondering whether Ciena's current share price reflects its true worth, the recent trading history gives you plenty to think about. The stock last closed at US$520.80, with returns of 2.6% over 7 days, 19.0% over 30 days and 111.7% year to date, plus very large returns over 1 year and the past 3 and 5 years. Recent coverage has focused on Ciena as a key player in communications technology, with attention on how its products fit into growing data and network demand. This context has...

If you are wondering whether Wintrust Financial at US$147.91 still offers value or is starting to look stretched, the recent share price and fundamentals give you some clear clues to work with. The stock has held up over the last week with a 0.2% decline. The 30 day return sits at 8.0% and the 1 year return at 35.6%, with longer term returns of 128.2% over 3 years and 108.7% over 5 years. Recent coverage has focused on Wintrust Financial as part of broader discussions around US regional...

FDA extends Priority Review for Savara’s molgramostim BLA in autoimmune PAP by three months following a major amendment. Regulator cites no new safety, efficacy, or manufacturing concerns in connection with the extension. Extension reflects ongoing review activity for Savara’s lead product candidate, ticker NasdaqGS:SVRA. Savara, listed on NasdaqGS:SVRA, focuses on therapies for rare respiratory diseases, with molgramostim as its most advanced program targeting autoimmune pulmonary alveolar...

If you are wondering whether ANI Pharmaceuticals at around US$78.64 is priced attractively or already reflects a lot of optimism, the starting point is to understand what the current share price implies about future expectations. The stock shows mixed recent returns, with a 2.8% decline over 7 days, a 6.2% gain over 30 days, a 0.3% return year to date, 12.6% over 1 year, 108.5% over 3 years and 136.3% over 5 years. Recent coverage around ANI Pharmaceuticals has focused on its position within...

If you are wondering whether TransMedics Group at around US$110.93 is still priced attractively or already baking in a lot of optimism, this article walks through the key valuation clues. The stock has had a mixed recent run, with a 4.3% pullback over the last 7 days, an 8.5% gain over 30 days, a 9.6% decline year to date, an 18.6% return over the past year, and a very large 3 year gain of around 40.2%. Recent headlines around TransMedics Group have continued to focus on its position in the...

Wondering if Axsome Therapeutics at around US$185.96 is offering fair value or stretching expectations? This breakdown will help you frame what the current price might be implying. The stock has seen a 14.9% return over the last 30 days and a 75.0% return over the last year. The year to date return sits at 4.1%, while the 7 day return is a 1.6% decline. Recent headlines around Axsome have focused on the company as a higher profile name within pharmaceuticals and biotech. This helps explain...

Instacart, listed as NasdaqGS:CART under Maplebear, has announced the acquisition of Instaleap. Instaleap operates a fulfillment and enablement platform across roughly 30 countries outside North America. The deal is intended to expand Instacart's enterprise services across Europe, Latin America, and the Middle East. Instacart's parent company Maplebear, trading at $42.17, is adding Instaleap to widen its international reach beyond its core North American base. The move comes after a 15.9%...

Verisk Analytics (NasdaqGS:VRSK) has agreed to acquire AccuLynx, a SaaS provider in the restoration and repair industry, in a pending US$2.35b deal. The company expects the transaction to support its property estimating solutions and to be accretive by the end of 2026. Recent collaborations include integrations with Roofr Inc. for insurance claim processing and Pilotbird for social media investigative reports. These moves expand Verisk's ecosystem for insurance and claims professionals...

Activist investor Land & Buildings has criticized Welltower's new executive compensation plan, describing it as unusually aggressive. The investor argues the structure could work against shareholder interests and weaken alignment between management and owners. The dispute focuses on governance and incentives at NYSE:WELL, rather than short term operating performance. For investors watching NYSE:WELL, this governance debate arrives with the shares at $208.75 and with very large longer term...

If you are wondering whether Boston Scientific at around US$62 a share is starting to look appealing on value, or if the price still has more to adjust, this article is for you. The stock has seen a 3.4% decline over the last week, an 11.0% decline over the last month, and year to date is down 34.5% with a 39.1% decline over the last year, even though the 3 year and 5 year returns sit at 19.1% and 42.4% respectively. Recent moves are playing out against a backdrop of ongoing interest in...

Maze Therapeutics (NasdaqGM:MAZE) completed a sizable underwritten public offering of common stock and pre funded warrants. The deal drew significant participation from both new and existing institutional investors. Proceeds are earmarked to advance Maze Therapeutics' research and development programs focused on serious diseases. Maze Therapeutics, trading at a recent share price of $25.81, has experienced sharp share price swings, with a 7 day return of an 8.1% decline and a 30 day return...

Tompkins Financial (TMP) opened 2026 with Q1 results that build on a strong finish to 2025, with trailing 12 month revenue of US$435.1 million and basic EPS of US$11.30 supported by Q4 2025 net income of US$96.2 million on revenue of US$193.8 million. Over the past year, revenue has moved from US$292.6 million to US$435.1 million on a trailing basis while basic EPS climbed from US$4.98 to US$11.30, alongside net profit margin at 37% versus 24.2% the prior year. This sets up a quarter where...

Wondering whether Array Technologies at US$8.11 is offering value or just noise? This article walks through what the current price might be saying about the stock. Over the short term, the share price move of 3.6% over 7 days and 4.9% over 30 days sits alongside a 16.2% decline year to date and a 61.6% return over the last year. Taken together, this gives you a very mixed picture. These moves come as Array Technologies continues to sit in a solar and renewables theme that regularly attracts...

If you are wondering whether IAC is attractively priced or if the recent buzz is already reflected in the share price, this article walks through the key signals that matter for valuation focused investors. IAC shares last closed at US$44.48, with returns of 0.3% over 7 days, 11.5% over 30 days, 13.9% year to date and 25.1% over 1 year, compared with a much weaker 3 year return of 4.3% and a 5 year return showing a 68.0% decline. Recent headlines around IAC have kept attention on how the...

Wondering whether Korn Ferry at around US$65.80 still offers value or if the easy gains are behind it? This article walks through what the current price might be implying. The stock has returned 0.1% over the last 7 days and 4.4% over the past month, with a 9.5% return over 1 year, set against a small year to date decline of 0.9% and a 47.0% return over 3 years. These moves sit against a backdrop where investors are paying closer attention to established business models and balance sheet...

Rogers (NYSE:ROG) reports that its turnaround plan is driving structural cost reductions and operational improvements. The company highlights better operating efficiency and traction in industrial, ADAS, and renewable energy markets. These updates follow a period of sales and profitability pressure and point to a shift in business momentum. Rogers, a specialty materials producer, is closely tied to demand trends in sectors such as industrial applications, advanced driver assistance systems,...

Charter Communications Q1 2026 Earnings Snapshot Charter Communications (CHTR) has kicked off Q1 2026 with investors weighing a recent quarterly run that included Q4 2025 revenue of about US$13.6b and basic EPS of US$10.47 against a trailing twelve month EPS of US$36.90 on revenue of roughly US$54.8b. Over recent quarters, the company has seen revenue move from about US$13.9b in Q4 2024 to US$13.6b in Q4 2025, while quarterly basic EPS shifted from US$10.32 to US$10.47 across the same...

In the past week, Catalyst Pharmaceuticals reported stronger traction for its rare-disease drugs Firdapse and Agamree, alongside expectations for modest quarterly revenue growth supported by a solid balance sheet. This combination of growing product momentum and anticipation around upcoming earnings has drawn fresh attention to how Catalyst’s rare-disease portfolio may evolve in the global market. Now we’ll examine how this stronger Firdapse and Agamree momentum could reshape Catalyst...

Investors may be wondering whether Old Second Bancorp at around US$20 still offers value, or if most of the upside has already been priced in. The stock has recently seen an 8.8% decline over the last 7 days, set against a 2.0% return over 30 days, 2.7% year to date and 29.8% over 1 year. Recent coverage has focused on Old Second Bancorp in the context of broader bank sector sentiment and how investors are reassessing risk and return across regional financials. This background helps frame...

Wondering if Celsius Holdings at US$34.59 is priced for its past success or offering value for the years ahead? This article breaks down what the current price tag might mean for you. The stock has seen a 1.9% decline over the last 7 days, 3.7% over 30 days, and 27.6% year to date, while the 1 year return sits at a 5.9% decline and the 3 and 5 year returns are 8.6% and 81.1% respectively. Recent news around Celsius Holdings has focused on its position within the broader beverages space, as...

Valmont Industries (NYSE:VMI) plans to host an Investor Day on June 16, 2026. Senior leadership is expected to share long term strategy updates and key value drivers. The event will cover the company’s infrastructure and agricultural segments for in person and webcast audiences. Valmont Industries focuses on infrastructure and agricultural solutions, including utility structures and agrotechnology. Investor Day gives you a chance to hear directly from management about how these businesses...

Oceaneering International (NYSE:OII) reported one of its strongest quarterly order intakes since 2020, with around US$1b of orders in Q1. The company introduced Momentum, a next generation electric work class ROV, expanding its subsea robotics offering. These updates add new detail on Oceaneering's order backlog and technology roadmap beyond recent earnings headlines. Oceaneering International, a long established provider of subsea services and robotics for energy and industrial customers,...

Investors may be wondering if Green Plains at US$15.92 is still attractively priced after a strong run, or if they might be late to the story. The stock has returned 7.4% over the last week and 54.9% year to date, with a 344.7% return over the past year contrasting with weaker 3- and 5-year figures of negative 53.4% and negative 46.6%. Recent coverage has focused on Green Plains as an actively traded biofuels name, with attention on how the share price has shifted alongside changing...